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1. Introduction 
Hepatitis B and C (HBV&HCV) viruses are two hepatotropic non-cytopathic viruses able to 
evade immune system efficiently as mechanism to persist in infected hosts. To fight against 
a viral infection the host displays two kinds of immune responses: the innate and adptive 
responses. The innate response is the first immunological barrier and it is essential in 
cytopathic viruses. This response limits viral spreading but also acts as adaptive response 
activator through antigen presentation to viral specific cells. Adaptive response is the 
second line in the immunological defense. It plays a major role in non-cytopathic viral 
infections because this type of viruses behaves as an intracellular parasite and they remain 
occult to the innate system. 
1.1 General features of Innate Immune response 
The liver is a unique anatomical and immunological site in which antigens-rich blood from 
the gastrointestinal tract is passed through a network of sinusoids and scanned by antigen-
presenting cells and lymphocytes. It is selectively enriched in macrophages (Kupffer cells), 
natural killer cells (NK) and natural killer T cells (NKT) which are key components of the 
innate immune system (Racanelli & Rehermann, 2006). 
Innate immunity generally plays a role immediately after infection to limit the spread of the 
pathogen and to activate the adaptive immune response (Guidotti & Chisari, 2006). 
Complex interplay between innate and adaptive immunity is the key for the resolution of 
acute infections. Innate response is induced after host recognition of common molecular 
patterns expressed by viruses, immediately after primoinfection, and providing a 
mandatory environment for triggering efficient adaptive immune responses. During hide 
and seek game of virus and host, one or more viral products get exposed and recognized by 
early immune response. This starts anti-viral control through direct cytopathic mechanisms 
(Koyama et al., 1998), antiviral effect by producing IFN type I (IFN-alpha/beta) by infected 
cells (Samuel, 2001), and activation of the cellular component of the innate immune system 
as natural killer (NK) cells and natural killer T (NKT) cells (Biron et al., 1999).  
Production of type I IFNs can be triggered directly by virus replication through cellular 
mechanisms that detect the presence of viral RNA or DNA (Alexopoulou et al., 2001), while 
NK cells are activated by the recognition of stress-induced molecules and/or the 
modulation of the quantity of major histocompatibility complex (MHC) class I molecules on 
the surface of infected cells (Moretta et al., 2005). 
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NK and NKT cells can be rapidly recruited to the site of virus infection and have the 
potential to recognize infected cells before MHC class I expression is significantly induced 
on the cell surface. Activated NK and NKT cells may participate in disease pathogenesis 
directly, by killing infected cells, and indirectly, by producing soluble factors that have 
antiviral activity, recruiting inflammatory cells into the infected tissue and shaping the 
adaptive immune response (Biron et al., 1999). 
1.2 General features of adaptive immune response 
Non-cytopathic viruses behave as intracellular parasites which are hidden to the immune 
system. They are not usually highly infectious but produce long-lasting diseases that allow 
them to spread the infection along the time. The host-virus relationship is a dynamic process 
in which the virus tries to decrease its visibility, whereas the host attempts to prevent and 
eradicate infection with minimal collateral damage to itself (Nowak & Bangham, 1996). 
To control non-cytopathic viral infections, it is necessary the activation of the adaptive 
immune system, and especially the cellular immune response. Naïve specific CD4+ and 
CD8+ T cells are primed by dendritic cells in the lymph nodes. Once these cells become 
activated, they change the phenotype into effector cells and migrate to the infected tissue, 
attracted by the chemokines produced by the parenchymal cells. Primed specific CD4+ cells 
are essential to allow the adequate activation of specific cytotoxic T cells by secretion of Th1 
cytokines (Larrubia et al., 2009a). This is very important because specific cytotoxic T 
lymphocytes play a major role in spontaneous infection resolution. These cells are able to 
recognize the infected cells and to destroy them by cytolytic mechanisms, but they also 
produce type-1 cytokines that eliminate the virus without producing tissue damage (Fig.-1). 
 
 
Fig. 1. Cytolitic and non-cytolitic mechanisms to destroy hepatotropic viruses by specific 
cytotoxic T cells 
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Both CD4+ and CD8+ cell activation depends on the engagement between T cell receptor 
and the MHC molecule/epitope complex plus the interaction between co-stimulatory 
molecules and their ligands (Choudhuri et al., 2005). When these cells have finished their 
effector task, they express negative co-stimulatory molecules and pro-apoptotic factors to 
switch-off their activity, and a subsequent constriction in the specific T cell population is 
produced.  After this event, a memory T cell population is maintained for decades to 
respond faster to a new infection, and in certain cases to keep under control viral occult 
infection (Appay et al., 2008).  
In this chapter the specific features of the immune response against two hepatotropic non-
cytopathic viruses (HBV&HCV) able to induce a persistent infection in human are reviewed. 
2. HBV immunopathogenesis 
HBV is an enveloped incomplete circular double strand DNA virus. This virus is spread 
around the world and more than 2 billion people have markers of current or past HBV 
infection, developing chronic infection in approximately 350 million people. Approximately 
a quarter of persistent infection patients will develop terminal liver disease. The infection is 
acquired by parenteral, vertical and sexual transmission, and although there is an efficient 
vaccine, this infection is still an overwhelming health problem, especially in developing 
countries. Natural HBV control is based on a competent immune response but this is not 
obtained in 5-10% of infected adults and up to 95% of newborns from HBeAg-positive 
mothers (Liaw et al, 2010).  Currently, there are different effective treatments able to control 
HBV replication but they are not very efficient in inducing either HBeAg or HB surface 
(HBsAg) Ag seroconversion (Perrillo et al, 2010). For this reason, it is interesting to 
understand the HBV immunopathogenesis to develop immunomodulatory strategies to 
restore an efficient anti-HBV immunoresponse. 
2.1 Life cycle of HBV 
Hepatitis B virus (HBV) is not directly cytopathic for the hepatocyte. During the early phase 
of HBV (before virus-specific T cells enter into the liver), there is no histological or 
biochemical evidence of hepatocyte damage (Guidotti et al., 1999). Moreover, when cellular 
immune responses are deficient or pharmacologically suppressed, HBV can replicate at high 
levels in the liver in the absence of detectable pathological consequences (Ferrari et al., 2003; 
Wieland et al., 2000). These results suggest that hepatocyte damage during HBV infection is 
an immune-mediated event. Therefore, this virus is capable to enter, replicate and spread in 
human hepatocytes without causing any direct damage. 
HBV is able to attach to the hepatocyte in a non-cell-type specific manner through cell-
associated heparan sulphate proteoglycans. Later, the virus binds irreversibly to an 
unknown hepatocyte-specific preS1 receptor. After that, two different entry pathways have 
been proposed: endocytosis and fusion. Finally, the cytoplasmic release of the viral 
nucleocapsid, containing the relaxed circular partially double stranded DNA (rcDNA), is 
performed. Then, the nucleocapsid with the rcDNA is transported to the host cell nucleus 
(Kann et al., 2007). Once rcDNA enters into the nucleus is repaired to complete the double 
strand DNA to produce the covalently closed circular DNA (cccDNA). The cccDNA stays 
stable in the hepatocyte nucleus for decades, and it is organized as chromatin like structure 
(minichromosome) (Levrero et al., 2009). The cccDNA utilizes the cellular transcriptional 
machinery to produce all viral RNAs necessary for protein synthesis and viral replication. 
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From an immunological point of view, the cccDNA is extremely important since it will 
persist in most of the hepatocytes and it is not possible for the immune system to destroy it. 
For this reason, even if the immune response is able to control HBV infection, it does not 
mean HBV eradication because cccDNA persists as occult HBV infection in the hepatocytes 
(Larrubia, 2011; Rehermann et al., 1996). From the pregenomic HBV RNA reverse 
transcription is performed by HBV DNA polymerase. This new HBV DNA can be either re-
imported into the nucleus to form additional cccDNA molecules or can be enveloped with 
HBV translated proteins for secretion (Urban et al., 2010). 
2.2 HBV acute infection 
2.2.1 Innate immune response during acute HBV infection 
During HBV primo-infection, replication can be efficiently limited by type I IFNs (Wieland 
et al., 2000; McClary et al., 2000). Nevertheless, data on acutely infected chimpanzees have 
shown a lack of detection of genes associated to innate response in the liver during the entry 
and expansion phase of HBV (Wieland et al., 2004). During this phase, HBV can replicate 
unchecked to extremely high levels. It has been proposed that, because HBV replicates 
within nucleocapsid particles, viral replicative intermediates of single-stranded RNA or 
viral DNA, which are strong activators of type I IFN genes, are protected from cellular 
recognition (Wieland & Chisari, 2005). 
Such early events are difficult to analyze during natural infection in humans, because HBV-
infected patients are mainly detected after clinical hepatitis, which occur 10-12 weeks after 
infection. Nevertheless, it is interesting to note that the lack of early symptoms (such as 
fever and malaise) in HBV-infected patients, typical of other human viral infections, 
constitutes an indirect evidence of the defective type-I IFN production during the early 
phases of HBV infection. 
In a cohort of patients, sampled in the pre-clinical phase and followed up to infection 
resolution, serum concentrations of IFN-alpha remained barely detectable during the early 
incubation phase and throughout the peak of viral replication and subsequent viral load 
reduction. Circulating IFN-alpha levels in patients with acute HBV infection at the time of 
peak of viremia were no significantly greater than at the time of infection resolution. 
Similarly, IFN-kappa and IL-15, which are important for induction of NK effector function, 
were not induced during the peak of viremia (Dunn et al., 2009). 
Consequently, HBV can be considered as a “stealth virus”, capable of sneaking through the 
front line of host defenses. It is possible that this situation of immune suppression might be 
activated by HBV replication. IL-10 is a potent immunosuppressive cytokine that can inhibit 
both innate and adaptive immunity. In fact, a close correlation between circulating IL-10 and 
HBV-DNA levels have been observed. IL-10 increased early in the course of infection, in 
parallel with the rapid increase in HBV viral load and antigenaemia and before the onset of 
inflammation. Moreover, the reduction of IL-10 coincided with either the termination of 
viremia or with HBeAg seroconversion. Consequently, there may be an active suppression 
of NK responses mediated for IL-10. In further support of this, addition of exogenous IL-10 
during in-vitro experiments was able to suppress NK cell IFN-gamma production which 
was recovered upon blocking IL-10 and its receptor (Dunn et al., 2009). 
Although no induction of type-I interferon is observed, within hours after HBV infection, 
there is a transient release of IL-6 and other proinflammatory cytokines (IL-8, tumour 
necrosis factor (TNF) alfa, IL-1B). The IL-6 released was shown to control HBV gene 
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transcription and replication in hepatocytes shortly after infection, ensuring an early control 
of virus replication, thereby limiting the activation of the adaptive immune response and 
preventing death of the HBV-infected hepatocytes in the early phases of infection (Hosel et 
al., 2009). The production of IL-6 and other cytokines seems transient after HBV infection. 
Interestingly, HBV replication tends to increase 3-4 days after infection, when IL-6 level has 
returned to baseline. This may suggest that the virus actively counteracts the action of IL-6, 
like occurs during the human cytomegalovirus infection (Gealy et al., 2005). 
However, a role for the innate immune response in the control of early HBV replication 
should not be dismissed. A study performed in woodchucks (Guy et al., 2008) observed a 
NK and NKT cell response within hours after inoculation with a liver-pathogenic dose of 
woodchuck hepatitis virus. These immune responses were at least partially capable of 
limiting viral propagation but were not followed by a prompt adaptive T cell response, 
which was delayed for 4-5weeks. Chimpanzees able to control the virus show a typical acute 
phase of disease with a robust activation of IFN-gamma, and TNF-alpha (Guidotti et al., 
1999). It is possible that this initial host response to HBV is primarily sustained by NK and 
NKT cells, that are capable to inhibit HBV replication in-vivo (Kakimi et al., 2000), as shown 
by the early development of NK and NKT responses in healthy blood donors who became 
hepatitis B surface antigen and HBV DNA positive (Fisicaro et al., 2009). Also, an early 
activation of NK and NKT cells in a woodchuck model of acute hepatitis B infection has 
been shown.  In this model NK and NKT cells induced a transient, but significant reduction 
of virus replication (Guy et al., 2008).  
In human, a study performed in two seronegative blood donors who became positive for 
HBsAg and HBV DNA, who were monitored throughout very early stages of infection, 
demonstrated that the human innate immune system is indeed capable of sensing HBV 
early after infection and of triggering a NK/NKT cell response to contain HBV infection and 
to allow a timely induction of adaptive response (Fisicaro et al., 2009). 
Therefore, rather than being silent, hepadnaviruses may be efficient at counteracting the 
actions of the innate immune system early after infection. There is a growing body of 
evidence suggesting that HBV could inhibit innate responses by regulating the expression of 
Toll-like receptors (TLRs), which are major sensors of viral infection in immune-specialized 
and non-specialized cells (Barton, 2007). HBV is able to suppress toll-like receptor-mediated 
innate immune response in murine parenchymal and non-parenchymal liver cells (Wu et al., 
2009). Indeed, the expression of TLR1, TLR2, TLR4 and TLR6 is significantly lower in 
peripheral blood mononuclear cells (PBMC) and hepatocytes from chronic hepatitis B (CHB) 
patients (Chen et al., 2008). Furthermore, flow cytometric analysis has shown that the 
expression of TLR2 in PBMC, from CHB patients is significantly decreased.  TLR2 
expression on PBMC has been correlated with the HBsAg plasma levels (Riordan et al., 2006) 
and HBeAg protein (Visvanathan et al., 2007). Recently, an immunomodulatory role of 
HBeAg on innate immune signal transduction pathways, via interaction and targeting of 
TLR-mediated signalling pathways, has also been shown (Lang et al,.2011). 
Moreover, dendritic cells (DC) exhibit functional impairment in hepatitis B virus carriers. 
Plasmocytoid (p)-DC are the major type-I interferon producing cells and sensors of viral 
infections because they express both TLR7 and TLR9 that respectively recognize, even in 
absence of viral replication, single-stranded RNA and unmethylated cytosine-guanosine 
dinucleotide motifs (Fitzgerald-Bocarsly et al., 2008). A recent study reported that, in CHB 
patients, there was a reduction of TLR-9 expressions in pCDs, which correlates with an 
impaired IFN-alpha production by these cells (Xie et al., 2009). 
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Altogether, these data suggest that HBV infection can alter innate immune responses, 
triggered by both specialized cells and hepatocytes, through down-regulating functional 
expression of TLR. Currently, whether HBV is a stealth virus for the innate immune 
response or is able to block it efficiently is a matter of debate. 
2.2.2 Adaptive response during acute HBV infection 
Despite of the lack of proper innate response activation, this does not affect to adaptive 
response during HBV primo-infection. HBV-specific T cell response appears soon after the 
exponential HBV replication phase (Webster et al., 2000). Both, CD4+ and CD8+ specific 
responses are present and they are polyclonal, vigorous and multi-specific, when the viral 
control is obtained, while these responses are impaired when the infection progresses over 
chronicity (Maini et al., 1999). HBV control is achieved through the labor of HBV-specific 
CD8+ T cells. These cells are able to recognize infected hepatocytes and to destroy them by 
apoptosis, but also they produce type-I cytokines, such as gamma-interferon and TNF-
alpha, which are capable of non-cytopathic HBV clearing (Ferrari et al., 2003; Guidotti & 
Chisari, 2001). This response to become fully activated needs the adequate stimulation by 
professional antigen presenting cells and the correct regulation by specific CD4+ cells. HBV-
specific CD8+ T cells are responsible of HBV control, but they also initiate a minor liver 
damage. In fact, most HBV DNA is eliminated by non-cytolitic pathways before amino-
transferases elevation is detected. Nevertheless, the secreted IFN-gamma by these cells, in 
addition to the chemokines produced by infected hepatocytes, attracts non-specific 
mononuclear cells and polymorphonuclear cells, which are responsible of liver damage 
amplification (Guidotti & Chisari, 2006). This phenomenon is also acting in the pathogenesis 
of chronic disease. Specifically, during persistent infection, the HBV specific response is 
impaired and unable to control the infection, but the hepatocytes continue secreting 
chemokines to attract effector T cells. However, non-specific inflammatory cells are also 
attracted and they are the cause of the low grade of persistent liver damage (Bertoletti & 
Maini, 2000). 
During the acute phase of infection, antibodies (Ab) against HBsAg, HBeAg and core (HBc) 
Ag are produced by activated B cells. HBsAb and HBeAb production is T helper dependent, 
while HBcAb secretion is dependent and non-dependent from T helper action (Milich & 
Chisari, 1982). HBs antibodies are produced very early after infection, but they are not 
detected because they generate complexes with circulating antigens, and therefore they are 
not detected until the virus is controlled. HBs antibodies prevent viral spreading from one 
to another hepatocyte and also block circulating HBV. The detection of these antibodies 
means HBV control and confers natural immunity against re-infection. Observation of 
HBsAb occurs when HBV is controlled by immune system, and these are neutralizing Abs 
that will avoid HBV re-infection in case of a new encounter with the virus. HBc Abs are not 
neutralizing and they indicate HBV contact. When HBc IgM subtype is positive it means 
acute infection or HBV flare-up during chronic infection. HBe Abs appear before HBs Abs 
during acute HBV recovery and also when chronic patients shift from a replicative to a non-
replicative phase. Moreover, HBe Abs are also present during the HBV chronic replicative 
phase, when the infecting virus displays a pre-core mutation that avoids HBe Ag production 
(Maruyama et al., 1994; Milich & Liang, 2003). 
During adulthood, most of acute HBV infected cases recover and develop natural immunity 
due to the combination of a polyclonal, vigorous and multispecific cytotoxic and helper 
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response (Guidotti & Chisari, 2006). After a self-limited infection, a T cell response 
constriction is observed and a central memory T cell population is generated. In these cases, 
a long-lasting protective T cell response is developed. These cells keep under control the 
intrahepatic HBV traces for decades. In fact, in HBV recovered patients it is possible to 
demonstrate a T1 orientated multispecific cytotoxic and helper response, decades after 
primo-infection, and those responses are associated with the observation of HBV DNA in 
sera or PBMC using ultra-sensitive PCR techniques. These data show that HBV recovery 
does not mean HBV eradication, since despite of clinical recovery it is possible to 
demonstrate HBV viral traces that are maintained under control due to the adaptive 
memory immune response (Larrubia, 2011; Penna et al., 1996; Rehermann et al., 1996). 
2.3 HBV chronic infection 
Around 5-10% of HBV primoinfection progresses to chronicity in adult infection, while it 
reaches 95% of newborns from HBeAg-positive mothers and approximately 50% during 
childhood infection (Liaw et al., 2010). The development of a persistent HBV infection is 
based on a failure of HBV-specific response due to the induction of an anergic and pro-
apoptotic status on this response because of the high viral pressure (Maini et al., 2000a; 
Webster et al., 2004). Several mechanisms have been involved in the impairment of specific T 
cell response. Specific T cells behave as anergic cells with progressive impairment of type-1 
cytokine production, such as IL-2, IFN-gamma and TNF-alpha. The cytotoxic T cells are 
neither able to proliferate nor to kill infected hepatocytes after antigen encounter. 
Nevertheless, cytokines and chemokines produced in the infected liver are able to attract a 
non-specific inflammatory population causing the persistent liver damage. Several 
mechanisms are used by HBV to induce this anergic status, which will end-up in a pro-
apoptotic situation that could cause specific T cell deletion. Persistent high HBs 
antigenemia, massive production of defective viral particles and the toleraising liver 
environment induces an anergic condition on T cells. In fact, HBV infected liver is depleted 
in tryptophan and there is an accumulation in its toxic metabolite (IDO) which is able to 
induce immunotolerance (Larrea et al., 2007). Also, arginase I activity is increased during 
HBV infection provoking an arginine depletion on T cells which causes a CD3ζ down-
regulation. The effect of CD3ζ lower expression translates into IL-2 production impairment 
by HBV-specific CD8+ cells (Das et al., 2008). Interestingly, in the HBV infected liver is 
increased the secretion of immunosuppressive cytokines. IL-10 is produced by dendritic 
cells and Kupffer cells while transforming growth factor-beta (TGF-ǃ) is secreted by stellate 
cells. The level of these cytokines correlates with HBV disease activity during chronic and 
acute infection (Dunn et al., 2009). Other escape mechanisms involve TRAIL-mediated 
deletion of HBV-specific CD8+ cells by NK cells (Dunn et al., 2007). Moreover, regulatory T 
cells can cause HBV-specific T cell activity suppression (Furuichi et al., 2005). On the other 
hand, persistent HBV infection favors the up-regulation of pro-apoptotic molecule Bim. This 
molecule mediates premature HBV specific cytotoxic T cell death following intrahepatic 
antigen presentation (Lopes et al., 2008). Another common mechanism, induced by HBV to 
evade immune system, is the induction of negative co-stimulatory molecules such as CTLA-
4, PD-1, Tim3 and Lag3. Excessive co-inhibitory signals drive T cell exhaustion during 
chronic HBV-infection (Maini & Schurich, 2010). Finally, HBV is also able to evade specific 
immune response by developing escape mutation at cytotoxic and helper immunodominant 
epitopes (Maini et al., 2000b). 
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2.3.1 Adaptive response during chronic HBV infection 
Chronic evolving infection is characterized by several progressive phases with different 
adaptive response features. The first stage is called immunotolerant phase. This is typical 
for countries with high rates of mother to child HBV transmission, but it is not seen in 
Western countries, where this route of transmission is not common. During this phase, 
HBV viral load is extremely high, but the liver damage and the anti-HBV immune 
response are absent. Several studies from D. Milich group, in HBe+ transgenic mice, have 
shown that the lack of HBV-specific immune response is due to some properties of 
HBeAg. This viral protein is able to cross the placenta to reach the offsprings thymus, 
where this is considered a self-antigen, eliciting HBe/HBc Ag-specific T helper cell 
tolerance in uterus (Milich et al., 1990). Moreover, during this phase, high HBV viral load 
inhibits adaptive immune response. In fact, frequency and function of HBV-specific T cells 
is inversely correlated with HBV viral load (Boni et al., 2007; Webster et al., 2004) (Fig.-2). 
In the natural history of chronic HBV infection, this phase is followed by the immuno-
clearance stage. This is the common starting point in persistent infection in Western 
countries. This phase is characterized by viral replication and liver damage fluctuations. 
Even though the specific immune response is quite inefficient, it is still able to obtain 
certain HBV control. During this phase, HBeAg seroconversion and HBV pre-core mutant 
selection is possible. HBe seroconversion allows the change to another HBV infection 
phase with a higher viral control and lower liver damage. HBe seroconversion is faster in 
individuals with certain polymorphisms at IL-10 and IL-12 genes. In these cases, high 
levels of IL-10 and IL-12 are observed and they are a predictor of spontaneous HBe 
seroconversion (Wu et al., 2010). Another typical feature of the immuno-clearance phase is 
the presence of HBV exacerbations, characterized by HBeAg level increase followed by 
transaminase level raise. The HBeAg level increase induces an activation of HBc/HBe 
specific response activation, after this a decrease in HBeAg and transminase level is 
observed, followed by a specific T cell response constriction. This data show that HBV-
specific T cell activation due to HBeAg level is causing acute exacerbations in HBeAg+ 
chronic patients (Frelin et al., 2009). This phenomenon can lead to liver damage 
generation, HBe seroconversion and pre-core mutant selection. During these HBV acute 
exacerbations, HBV-specific cytotoxic T cells destroy wild-type HBV infected hepatocyte 
producing liver damage. Moreover, if along this stage HBV pre-core mutants emerge, 
these cytotoxic T cells can select them, since the infected hepatocytes with these variants 
are not recognized properly by cytotoxic T cells. In fact, liver infected cells by the wild 
type virus are eliminated more efficiently by specific cytotoxic T cells than cells infected 
by the pre-core mutant. This is because wild-type infected cells presenting HBc and HBe 
epitopes are better targets for cytotoxic T cells than cells infected by HBV pre-core mutant 
expressing only core epitopes (Frelin et al., 2009). This situation leads to HBe antigen 
negative form of chronic hepatitis B with persistent liver damage, which is different to the 
wild-type HBe seroconversion where the infection can be consider inactive. This last one 
is the third phase of the chronic HBV natural history which is called low or non 
replicative phase, and corresponds to the clinical inactive carrier state. In this stage viral 
load and liver damage is very low. During this phase HBV-specific T cell responses are 
present and are quite efficient despite lack of liver damage. These cells are very competent 
in controlling infected hepatocytes, preventing HBV spreading and the development of 
liver infiltration by non-specific inflammatory cells, which are the cause of persistent liver 
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damage during chronic active hepatitis B. Therefore, it is considered that during the 
low/non-replicative phase HBV is under a partial control by HBV-specific response 
(Maini et al., 2000a). At this stage, it is possible to observe HBV reactivation associated 
with hepatitis flares, mainly in the case of infection by HBV pre-core mutants. This last 
phase of HBV natural history is called reactivation phase. The immunological causes of 
these reactivations are not very well known yet. During these hepatitis flares is not 
possible to demonstrate the presence of HBV-specific T cell reactivity, but it is observed 
NK cell activation which correlates with the degree of liver damage (Dunn et al., 2007). 
Therefore, in this last step of chronic HBV natural history, the innate response could be 
involved. 
 
 
Fig. 2. FACS® dot-plots from peripheral blood mononuclear cells of HBV infected patients 
with different HBV control stained directly ex-vivo with Ab against CD8 plus multimeric 
HLA-A2/core 18-27 complexes. A negative correlation between viral control and frequency 
of HBV-sepcific CD8+ cells is observed. Figures in the upper right quadrant show the 
frequency of HBV-specific CD8+ cells out of total CD8 population. 
In summary, HBV is not ever completely eliminated from the infected host, but there is a 
gradient of control according to the functional efficiency of HBV-specific response. In 
patients with HBV natural immunity, they present a HBV occult infection with a very 
efficient control by CD4+ and CD8+ specific HBV T cells. This immune control is partial in 
patients in the inactive carrier state and completely inefficient in cases with chronic active 
hepatitis (Boni et al., 2007; Maini et al., 2000a; Zerbini et al., 2008). Strategies directed to 
restore anti-HBV adaptive response could help in the permanent infection control. 
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3. HCV immunopathogenesis 
The hepatitis C virus (HCV) is an enveloped; positive stranded RNA virus and represents 
the Hepacivirus genus in the Flaviviridae family. It has been estimated that more than 170 
million people are infected with HCV, since clinical identification and molecular cloning of 
HCV in late 1980s. This virus is spread by contact with infected blood and body fluids. 
Approximately 80% of infections succeed in establishing a chronic infection with the 
potential for developing severe liver diseases such as cirrhosis and hepatocellular carcinoma 
(HCC) (Lavanchy, 2009; Tsukuma et al., 1993).  
No effective vaccine against HCV is available till date. Current standard-of-care therapy for 
HCV infection as peg-interferon-alpha and ribavirin (Pawlotsky, 2004), has limited efficacy, 
in particular against the genotype 1 virus (Fried et al., 2002; Manns et al., 2001). An extended 
search for new therapy is progressing, already passed for marketing authorization of the 
protease-inhibitors (Poordad et al, 2011). A major concern with new therapy is rapid 
development of drug-resistant viral mutants. Due to the failure or side effect of the 
treatment, stepping forward for understanding the immunopathogenesis of HCV infection 
is essential in the development of a therapeutic vaccine and immunomodulatory treatments 
for chronic infections. 
Due to the lack of adequate cell culture systems, HCV studies have been slowed down for a 
long time, but continuous progress in the last few years it has overcome this obstacle. In-
vivo model to study the biology of HCV have been significantly restricted due to the limited 
experimental availability of chimapanzees, the primary model for HCV (Alter et al., 1978; 
Bukh, 2004), and difficulties encountered in reproducing true infection in small animals. 
Two breakthroughs has been an important contribution to the field: firstly, subgenomic 
replicons (i.e. without structural genes) (Blight et al., 2000; Blight et al., 2003; Lohmann et al., 
1999), which are highly permissive for HCV replication (Blight et al., 2002) and secondly, 
HCV complete replication in cell culture (Lindenbach et al., 2005; Wakita et al., 2005; Zhong 
et al., 2005). However, it has long been recognized that these models are complicated by the 
particularly high error rate of the HCV RNA replicase (Rong et al., 2010). 
It is widely accepted that immune-mediated host-virus interactions are responsible for the 
outcome of HCV and pathogenesis of further severe diseases. In this chapter, it is covered 
how virus evades primary defense mechanisms. Finally, adaptive immune response escape 
mechanisms induced by HCV to become persistent are also analyzed. To be familiar with 
pathogenesis of HCV infection, a brief outline of HCV life cycle is provided below.  
3.1 Life cycle of HCV 
The development of HCV replicons (Blight et al., 2000; Blight et al., 2003; Ikeda et al., 2002; 
Lohmann et al., 1999), HCV pseudotyped particles (HCVpp) (Bartosch et al., 2003a) and most 
recently the infectious HCV cell culture system (Lindenbach et al., 2005; Wakita et al., 2005; 
Zhong et al., 2005) have advanced our understanding of the viral life cycle. Hepatocytes are 
the primary site of HCV infections. HCV life cycle begins with binding of the virus to cell 
surface receptors. The putative receptors, the tetraspanin protein CD81 (Bartosch et al., 
2003a; Hsu et al., 2003; Pileri et al., 1998; Wunschmann et al., 2000), the scavenger receptor 
class B member I (SR-B1) (Bartosch et al., 2003a; Grove et al., 2007; Kapadia et al., 2007; 
Scarselli et al., 2002) and the tight junction proteins claudin-1 (Evans et al., 2007) and 
occluding, (Benedicto et al., 2009; Liu et al., 2009; Ploss et al., 2009) have all been shown to 
enable HCV entry. In addition, the low-density lipoprotein receptor (Agnello et al., 1999; 
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Molina et al., 2007; Monazahian et al., 1999; Wunschmann et al., 2000), asialoglycoprotein 
receptor (Saunier et al., 2003), and glycosaminoglycans (heparin sulfate) are also involved, 
but their exact roles have not been determined. By clathrinmediated endocytosis (Blanchard 
et al., 2006; Meertens et al., 2006), HCV enters the cell. The virus undergoes an uncoating 
process by fusion between the viral envelope and endosomal membrane in the acidified 
endosomal compartment (Bartosch et al., 2003b; Haid et al., 2009; Hsu et al., 2003; 
Koutsoudakis et al., 2006; Lavillette et al., 2006; Tscherne et al., 2006) via E1/E2-mediated 
class II fusion (Garry & Dash, 2003; Lavillette et al., 2007), to expose the viral genomic RNA 
to host-cell machinery. About ~9.6 kb viral RNA genome is released into the host cell 
cytoplasm, to serve as template for the translation of the viral proteins. IRES-mediated 
translation of the HCV genome produces a single ~3,000 amino-acid polyprotein 
(Moradpour et al., 2004), which is processed by cellular and viral proteases into at least 10 
different protein products. These products include the structural proteins, which form the 
viral particle (the virus core and the envelope proteins E1 and E2), and the nonstructural 
proteins P7, NS3, NS4A, NS4B, NS5A and NS5B (Guidotti & Chisari, 2006). Viral replication 
is driven by minus strand intermediate. HCV double stranded RNA (dsRNA) is freely 
exposed in the cytoplasm of infected cell (Moradpour et al., 2004), which is recognizable for 
host innate immune system. Nucleocapsid is formed by assembling capsid proteins and 
genomic RNA and bud through intracellular membranes into cytoplasmic vesicles. Finally, 
by secretory pathway, mature enveloped virions release from the cell. 
3.2 Innate immune response during acute HCV infection 
The first response to HCV protein is thought to be IFN-ǃ production by infected hepatocytes, 
which are able to secrete type I IFN. The infected cells are sensed with pathogen associated 
molecular patterns (PAMP), Toll like receptor (TLR3) (Marie et al., 1998) and retinoic acid–
inducible gene I (RIG-I) (Bauer et al., 2001; Sato et al., 2000) by endosomal dsRNA and cytosolic 
dsRNA respectively, which is an essential intermediate in the HCV replication cycle, and thus, 
they may be important in the pathogenesis of hepatitis C (Saito et al., 2008). RIG-I recruits IFN-
ǃ promoter stimulator protein 1 (IPS-1; also called CARD adaptor inducing IFN-ǃ CARDIF), 
virus-induced signaling adapter (VISA), and mitochondrial antiviral signaling protein (MAVS) 
(Hoshino et al., 2006; Meylan et al., 2005; Xu et al., 2005), after ATP-driven activity dependant 
on recognition of viral protein (Honda et al., 2004). On other hand, TLR3 dimerization, due to 
leucine-rich repeats (Liu et al., 1998), recruits the adapter protein, Toll–IL-1 receptor domain–
containing adaptor inducing IFN-ǃ (TRIF). Both processes result in downstream signaling, 
nuclear translocation of IFN regulatory factor 3 (IRF3) and leads to stimulation of the 
transcription of a set of genes including IFN-ǃ (Kawai & Akira, 2008). Antiviral state, induced 
by secreted IFN ǃ, gives an alert to uninfected cells by activation of effector molecules. Binding 
of IFN -ǃ to cognate receptor complex lead to the activation of JAK/STAT pathway, which 
results in the induction of IFN-stimulated genes (ISGs) and lead to enhance the IFN response 
(Rehermann, 2009) (Fig.- 3).  
However, HCV has organized a number of countermeasures not only to inhibit the 
induction phase, but also interfere with the effector phase of the IFN system (Fig.- 3). It has 
been confirmed, in in-vitro studies, that HCV serine protease, NS3/4A is enable to cleave 
MAVS (Li et al., 2005b), TRIF (Li et al., 2005a), IPS-1 (Foy et al., 2003) and oligomerization of 
MAVS, which is part of signaling process (Kawaguchi et al., 2004; Li et al., 2005a; Li et al., 
2005b; Marie et al., 1998; Meylan et al., 2005; Sakamoto et al., 2000). Disruption of IRF-3 
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activation occurred by NS3 protein action (Liu et al., 1999) and it has been shown with 
different cell lines in-vitro studies (Kawaguchi et al., 2004; Marie et al., 1998). Another key 
player, HCV core, when over expressed in cell culture, disturbs antiviral activity via 
interfering in JAK/STAT signaling and ISG expression by inhibition of STAT1 activation. 
Simultaneously it induces its degradation (Gale & Foy, 2005; Lin et al., 2006) by induction of 
inhibitor of the JAK/STAT pathway SOCS3 (Bode et al., 2003), protein phosphatase 2A 
(PP2A), which ultimately reduces the transcriptional activity of ISG factor 3 (ISGF3) (Heim 
et al., 1999); and inhibition of ISGF3 interaction to IFN-stimulated response elements 
(Rehermann, 2009). HCV NS5A interferes with the function of ISGs by inhibiting 2′-5′ 
oligoadenylate synthetase (2′-5′ OAS) and leads to overall ISG expression impairment 
(Polyak et al., 2001). Protein kinase R (PKR) can negatively regulate HCV replication 
noncytolytically in cell cultures (Kim et al., 2004; Zhao et al., 2004), which can interacts with 
HCV NS5A and lost its function. Interestingly, HCV E2 acts as distraction target to PKR 
(Taylor et al., 1999). To sum up, the main targets of HCV proteins to evade immune response 
are interference with the induction of IFN synthesis, IFN- induced intracellular signaling 
and IFN-induced effector mechanisms (Fig.-3). 
 
 
Fig. 3. Evasion of Innate immune response by HCV: (A) Interference in IFN synthesis: 
Blocking of TLR 3 and RIG-1 signalling respectively, by cleavage of the adaptor molecule 
TRIF and IPS-1 via HCV NS3/4A; (B) Interference in IFN-induced effector mechanisms: 
Binding of IFN ǃ and its receptor with TYK2 and JAK1 kinase activation lead to form ISGF3 
complex, where this complex interact with IFN stimulated response elements (ISREs) within 
the promoter and enhancer region of ISGs to induce ISGs (such as 2’, 5’ OAS, PKR, IRF7) 
production in nucleus. HCV core induce SOCS1/3, which is the inhibitor of the JAK/STAT 
pathway and inhibits STAT1 phosphorylation, which inhibits assembly of trimeric ISGFs 
complex. Function of ISGs is inhibited by HCVE2 and HCV NS3/4A. 
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Dendritic cells (DC) are professional antigen presenting cells with important functions in 
antiviral immunity through activation of adaptive immune responses. Type-I IFNs are also 
produced by pDCs, which derive from the lymphoid lineage. Although, production of IFN 
alpha/beta, in early phase of infection occurs after recognition of ssRNA and dsRNA by 
TLR7 and TLR9 respectively, the mechanism is still not clear (Albert et al., 2008). The 
frequency of pDCs in the blood (Nakamoto et al., 2008) and their production of IFN-ǂ in 
HCV infection is reduced after in vitro stimulation (Bowen et al., 2008). The possible 
mechanism has been demonstrated in in-vitro studies. First, HCV core and NS3 activate 
monocytes by TLR2 signaling to produce TNF-ǂ (Izaguirre et al., 2003), which in turn 
inhibits IFN-ǂ production and induces pDC apoptosis (Bowen et al., 2008). Second, HCV 
itself inhibits IFN-ǂ production of pDCs (Diepolder et al., 1995). However, other studies 
revealed regular response to TLR stimulation by circulating pDCs of chronically infected 
individuals (Decalf et al., 2007; Longman et al., 2005) and they have high levels of 
endogenous type I IFNs without immuno-dysfuction (Albert et al., 2008). Although this 
defense mechanism is significant, the host rarely overcomes HCV infection, which suggests 
several other viral evasion mechanisms that are poorly or not understood yet. 
Another group of DCs, myeloid DCs (mDCs) derive from the myeloid lineage 
(Lanzavecchia & Sallusto, 2001; Steinman et al., 2003). Due to its tolerogenic and 
stimulatory role (Lanzavecchia & Sallusto, 2001; Steinman et al., 2003), mDCs have been 
broadly studied in HCV infection. mDCs have not been observed to be decrease in 
peripheral blood or dysfunctional in HCV chronic infected individuals in in-vitro studies 
(Kanto et al., 1999; Longman et al., 2004). Nevertheless, HCV proteins can interact with 
monocytes/macrophages through TLR2, inducing the IL-10 production, which hampers 
IL-12 production by mDC and IFN-alpha by pDC, or they directly inhibit DC 
differentiation (Szabo & Dolganiuc, 2005). IL-12 cytokine production by mDC is decreased 
in HCV patients in response to stimuli like CD40 L or poly (I:C) (Anthony et al., 2004), 
which can explain clearly the shift from Th1 to Th2 response in HCV patients. In-vitro 
studies indicates that DC expressing core and E1 proteins have lower stimulatory ability, 
which is associated to the lack of maturation after stimulation with TNF-alpha or CD40L 
(Sarobe et al., 2003).  
Other cells involved in the innate response are the NK cells. Functions of these cells include 
generating a cytotoxic response, regulatory cytokines production and control on DC 
maturation and amplitude of DC response, which may deeply impact on type of down-
stream adaptive immune responses. Response to HCV infection by NK cell is direct 
apoptosis induction of infected cells with production of antiviral cytokines (Golden-Mason 
& Rosen, 2006; Lodoen & Lanier, 2006). Moreover, NK cell depletion or dysfunction favor 
HCV persistence (Golden-Mason et al., 2008). The role of interactions between HLA class I 
and killer cell–Ig-like receptors (KIR) during HCV infection has been shown. KIR can 
regulate NK cell activities. However puzzling contradictions for this topic in different 
studies have been revealed (Montes-Cano et al., 2005; Paladino et al., 2007; Rauch et al., 2007). 
The importance of NK cells in the resolution of HCV infection is illustrated by the influence 
of genetic polymorphisms of KIR and their HLA ligands on the outcome of HCV infection, 
which was dependent on a homozygous HLA class I ligand background (Khakoo et al., 2004; 
Knapp et al., 2010; Stegmann et al., 2010). There is need to focus on clear understanding of 
functional and molecular HLA-KIR interactions to know about the possible way for NK cell-
mediated protection in animal models of HCV infection.  
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However, an increased proportion of NK cells expressing activating receptors, enhanced 
cytotoxicity and defective cytokine production have revealed in chronic HCV infection 
(Oliviero et al., 2009). Megan et al revealed that IL28A cytokine could significantly inhibit 
IFN-Ǆ production lead to NK cell inactivation (Ahlenstiel et al., 2010), which would be 
important to attenuate chronically activated NK cells. Consequently, the analysis of 
functional scene between NK cells and type 3 IFN in the immune response to virus will be 
required to understand the role of the NK in disease progression during HCV infection. 
3.3 Adaptive immune response 
The second barrier to control HCV infection is the adaptive immunity. This response has 
two arms to fight against pathogens; humoral and cellular immune response. Humoral 
immune response, that means neutralizing and non-neutralizing antibodies can endorse 
antiviral activity and pathogenesis (Guidotti & Chisari, 2006). Cellular immune response 
shows antiviral immunity by means of virus specific CD8 cytotoxic T lymphocytes (CTLs) 
and CD4 T helper cells, which play key effector and regulatory roles respectively. These T 
cells take part in viral pathogenesis of HCV by direct killing of infected cells or producing 
soluble factors able to clear the virus in a non-cytolytic manner, but also can lead to HCV 
pathogenic events, favoring direct liver damage and attracting non-specific inflammatory 
cells to perpetuate the liver inflammation (Guidotti & Chisari, 2006). 
3.3.1 Humoral immune response 
Neutralizing antibodies (nAbs) generally play a critical role for controlling initial viremia 
and protecting from re-infection in viral infections. However, the role of the humoral 
immune response in the clearance of HCV infection has been in the dark for a long time due 
to difficulties to determine relative role of antibodies to neutralize HCV. It can exclusively 
be evaluated by relevant model systems. It is thought that HCV clearance could occur in the 
absence of nAbs. If they are present alone, these Abs are inadequate to eradicate HCV in 
most of the cases in early studies (Dustin & Rice, 2007; Lechner et al., 2000a; Lechner et al., 
2000b; Logvinoff et al., 2004; Thimme et al., 2002). 
It has been proved that HCV specific T cells may compensate for lack of neutralizing 
antibodies to obtain HCV clearance (Semmo et al., 2006). However, due to the development 
of novel model systems (Bartosch et al., 2003a; Baumert et al., 1998; Lindenbach et al., 2005; 
Wakita et al., 2005; Zhong et al., 2005), it is possible to focus on HCV entry into host cells and 
neutralization process which demonstrated that nAbs are induced by patients who 
subsequently control (Lavillette et al., 2005) or resolve (Pestka et al., 2007) viral infection in 
the early phase of infection and contrary in chronic infection. This suggests that a strong, 
early, broad nAbs response may contribute to resolution of HCV in the acute phase of 
infection while delayed induction of nAbs may contribute to development of chronic HCV 
infection.  
Instead of the rapid, vigorous and multi-specific antiviral host immune responses, chronic 
patients have been shown to develop a delayed and inefficient neutralizing antibody 
response (Pestka et al., 2007) due to HCV escape mechanism (Zeisel et al., 2008). Recent 
studies evident that entry of HCV can be hampered or modulated by nAbs of chronic HCV 
patients (Gal-Tanamy et al., 2008; Haberstroh et al., 2008; Keck et al., 2009), while it is 
controversial in cell culture study (Grove et al., 2008). In addition, although nAbs are 
incapable to clear the virus in chronic infection, due to selection pressure exerting on viral 
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variants, they contribute to the evolution of the HCV envelope sequences to escape (Farci et 
al., 2000; von Hahn et al., 2007). It has been proposed that HCV stimulates B cells in a B cell 
receptor-independent manner in chronic infection (Racanelli et al., 2006) and may favor the 
development of lymphoproliferative and autoimmune diseases (Guidotti & Chisari, 2006). 
Although, in vitro studies evident that the neutralization ability of HCV-specific nAbs 
enhanced by complement activation against pseudotyped viruses (Racanelli et al., 2006), 
there is absence of direct experimental evidence about the presence of any of these Ab-
mediated functions during natural HCV infection. However, immune complexes are 
believed to play a pathogenetic role in the development of manifestations such as 
cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, and necrotizing cutaneous 
vasculitis during chronic HCV infection (Agnello & De Rosa, 2004; Amarapurkar & 
Amarapurkar, 2002; Manns & Rambusch, 1999). 
3.3.2 Cellular immune response 
Cytotoxic T lymphocyte (CTL) responses are essential to control HCV infection. Efficiency of 
antiviral CTL responses depends on where these cells are primed. Efficient antiviral CTL 
response is observed when it is primed in lymphoid organs, whereas within the liver, 
priming is more tend to induce T cell inactivation, tolerance or apoptosis (Guidotti & 
Chisari, 2006). A strong, multispecific and long-lasting T-cell immune response emerge to be 
important for control of viral infection (Dustin & Rice, 2007; Zhang et al., 2009). Persistent 
HCV unsuccessfully control by T effector cells is due to multiple causes, such as: HCV 
escape mutant generation, immunosuppressive effects exertion, Tregs induction, or effector 
T cell exhaustion or apoptosis (Bassett et al., 1999; Thimme et al., 2006; Thimme et al., 2001; 
Larrubia et al., 2011).  
3.3.2.1 Adaptive cellular response during acute HCV infection 
Vigorous CD4+ and CD8+ T cell responses targeting multiple HCV regions with intrahepatic 
production of IFN-Ǆ emerged in acute hepatitis C infection (Bowen & Walker, 2005; Lechner et 
al., 2000b; Thimme et al., 2001). Decreasing viral titer correlates precisely with the appearance 
of HCV-specific T cells and IFN-Ǆ expression in the liver (Shin et al., 2006). The appearance of 
HCV-specific T cells can be detectable in the peripheral blood or in the liver compartment 
several weeks after infection in humans or experimental chimpanzee models (Dustin & Rice, 
2007; Rehermann, 2009), respective with primary peak of transaminases and irrespective of 
clinical outcome (resolution or chronicity). Delayed emerging of antigen-specific responses are 
also essential for the HCV control (Rehermann, 2009).  
The protective function of CD4+ T cells appear to be due to the production of antiviral 
cytokines, but also their helping nature to antiviral B cells and in maintenance of CD8+ T cell 
memory. The HCV clearance has been observed and correlated with vigorous proliferation of 
specific CD4+ T cells (Diepolder et al., 1995; Missale et al., 1996) with concurrent IL-2 and IFN-Ǆ 
production (Kaplan et al., 2007; Urbani et al., 2006a). The early sustained development of CD4+ 
T cell response needs to be successful for viral clearance (Urbani et al., 2006a). Whereas, HCV-
specific CD4+ T cell responses are not observed in chronic HCV infection. Moreover, the 
recurrent viremia has been correlated with loss of previous strong CD4+ T cell responses after 
several months of viral clearance (Gerlach et al., 1999; Nascimbeni et al., 2003). Studies on the 
relative importance of CD4 help in spontaneous recovery in acute HCV infection 
demonstrated that fact (Smyk-Pearson et al., 2008). CTL priming in presence of CD4 help is 
critical factor in protective function (Urbani et al., 2006a).  
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On the other hand, the magnitude of CD8+ T cells response in acute HCV infection does not 
correlate with the clinical or viral outcome (Francavilla et al., 2004; Kaplan et al., 2007; Urbani 
et al., 2006a). Expression of a dysfunctional phenotype with weak proliferation, low IFN-Ǆ 
production, impaired cytotoxicity and increased levels of the well known exhausted 
phenotype programmed death-1 receptor (PD-1) are found in HCV infection, irrespective of 
infection progression (Bowen et al., 2008; Keir et al., 2007; Nakamoto et al., 2008; Sharpe et al., 
2007; Trautmann et al., 2006; Urbani et al., 2006b; Larrubia et al., 2011). Antigen-dependent 
reactivity of HCV-specific CD8+ T cells has been proved by a rapid decay of CD8+ T cell 
responses during antiviral therapy (Rahman et al., 2004). However, the appearance of self-
sustaining memory T cells (CD127+ memory HCV-specific CD8+ T cells and CD4+ T cells) 
are necessary to control HCV infection (Lechner et al., 2000b; Thimme et al., 2001; Urbani et 
al., 2006a). In fact, years after HCV control due to anti-HCV treatment it is possible to find 
HCV traces in association with HCV-specific T cell reactivity. These data suggest that HCV-
specific memory T cells are essential to clear HCV infection completely after the initial acute 
clearing (Veerapu et al., 2011). 
3.3.2.2 Adaptive cellular response during chronic HCV infection 
Complete resolved HCV patients exhibit broader CTL responses with higher functional 
avidity and wider cross-recognition ability than patients with persistent HCV infection 
(Yerly et al., 2008). There are evidences that demonstrate rapid mutation in HCV genome, T 
cell exhaustion because of expression of inhibitory molecules (Fig.-4), immune regulatory 
cytokine induction and immune modulatory T reg cell activation, which are main reasons 
for HCV persistence in chronically infected patients (Hiroishi et al.2010; Pavio & Lai, 2003; 
Seifert et al., 2004; Tester et al., 2005; Larrubia et al., 2011). 
 
 
Fig. 4. FACS® dot-plots and histogramas of CD8+ cells from HCV patients with different viral 
control. CD8+ cells were stained with Abs anti IFN-gamma and anti-PD-1 plus pentemeric 
HLA-A2/NS3-1406 peptide complexes. A negative correlation between PD-1 expression and 
IFN-gamma production by HCV-specific T cells according to viral control is shown. 
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Like Retrovirus, HCV polymerase has high replication rate and lack of proofreading 
capacity, which permit a rapid virus escape from emerging humoral and cellular immune 
responses and lead to persistent infection (Chang et al., 1997; Tester et al., 2005). Mutation 
study in early HCV infection in HLA class I restricted epitopes targeted by CD8+ T cells are 
associated with persistence (Ray et al., 2005; Timm et al., 2004), which proved indirectly that 
HLA-restricted CD8+ T cells exert selection pressure. Furthermore, the HLA alleles can 
influence infection outcome (Neumann-Haefelin et al., 2006).  
The secretion of certain immuno-regulatory cytokines is also related with HCV persistence. 
IL-10 cytokine is found to increase in chronic HCV infection (Piazzolla et al., 2000). In 
chronic HCV patients, the suppression of IFN-Ǆ production and proliferation of virus-
specific CD4+ and CD8+ T cells have been observed in livers with IL-10–producing HCV-
specific CD8+ T cells (Accapezzato et al., 2004). IL-10 produced by monocytes or NK cells 
downregulates effector T cell responses. For instance, monocytes secrete IL-10 in response to 
HCV core–mediated TLR2 stimulation in vitro (Dolganiuc et al., 2006). IL-10 producing 
HCV-specific CD8+ T cells inhibits IFN-ǂ production (Duramad et al., 2003), but also 
promotes apoptosis of pDCs (Dolganiuc et al., 2006), and induces liver infiltration of 
chronically infected individuals, suggesting that they modulate liver immunopathology to 
favor HCV persistence (Accapezzato et al., 2004). In addition, intrahepatic HCV-specific IL-
10 producing CD8+ T cells prevent liver damage during chronic disease (Abel et al., 2006). 
Moreover, TGF-b is also involved in antiviral immune suppression and chronic HCV 
infection evolution (Alatrakchi et al., 2007). To sum up these data, regulatory cytokines such 
as IL-10 or TGF-beta decrease liver inflammation, after affecting the protective immune 
response, developing a dual task. First of all, they impair T cell responses to allow viral 
persistence but also decrease liver damage to extend host survival.  
Regulatory T cells (Tregs) are important to control the balance between host damage and 
viral control produced by specific immune response. In cases of excessive immune response, 
that could be harmful for the host, these cells can induce immune-tolerance to the viral 
epitopes. Tregs are derived from natural or induced T cell populations, in which natural 
CD4+ Tregs are generated during normal T cell development in the thymus, whereas 
induced Tregs are generated from mature T cells (Bluestone & Abbas, 2003). T cell subset 
with suppressive function, CD4+ CD25+ FoxP3+ regulatory T (Treg) cells, engages in the 
control of auto-immunity and immune responses, through various mechanisms including 
the inhibition of APC maturation and T-cell activation (Shevach, 2009). No difference has 
been found in the frequency of Treg cells and the extent of suppression irrespective of the 
outcome of the infection (Manigold et al., 2006). However, higher Tregs frequency has been 
observed in chronic HCV infected patients than in resolved patients (Boettler et al., 2005; 
Cabrera et al., 2004; Rushbrook et al., 2005; Sugimoto et al., 2003). Interestingly, depletion of 
CD25+ cells could enhance responsiveness of the remaining HCV-specific effector cells in 
vitro (Boettler et al., 2005; Cabrera et al., 2004; Sugimoto et al., 2003), which suggest a 
fundamental role of Tregs in the establishment of chronic HCV infection. Moreover, Treg 
cells are induced and proliferate in chronic HCV infection and appeared to alter liver 
inflammation (Zerbini et al., 2008). Conversely, Programmed Death ligand-1 (PDL-1) 
mediated inhibition limits the expansion of Tregs by controlling STAT-5 phosphorylation 
(pSTAT-5) (Franceschini et al., 2009), which can diminish suppressive function of Tregs, lead 
to viral load control and ultimately ensure long-lasting survival of the host. 
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Fig. 5. Scheme showing the balance between co-stimulatory/apoptotic molecules and HCV-
specific CTLs reactivity according to infection outcome. Neg.: negative. Pos.: positive. CTLs: 
cytotoxic T lymphocytes. HCV: hepatitis C virus. (+): possible molecules induced by HCV 
infection. (-): possible molecules down-regulated by HCV infection. 
HCV is able to induce the up-regulation of different negative co-stimulatory molecules in 
order to provoke an anergic status on HCV-specific T cells. Expression of the inhibitory 
receptor PD-1 is one of these molecules involved in the generation of a state of exhaustion 
on HCV-specific CD8+ T cells during chronic HCV infection (Barber et al., 2006; Larrubia et 
al., 2009b). Importance of expression of PD-1 in HCV-specific T cell failure mechanism has 
been observed (Golden-Mason et al., 2007; Radziewicz et al., 2007), which can hinder by 
mutation in T cell epitopes (Rutebemberwa et al., 2008). In addition, blocking of PD-1 
signaling resulted in the functional restoration of blood-derived HCV-specific CD8+ T cell 
responses in chronic infection (Penna et al., 2007; Radziewicz et al., 2007). However, the PD-1 
alone is not sufficient in defining exhausted HCV-specific CD8+ T cells during HCV 
infection. To restore function of HCV-specific T cells isolated from liver biopsies of infected 
patients, there is need of CTLA4 blockade in addition to PD-1 blockade (Nakamoto et al., 
2009). In addition, the co-expression of other inhibitory receptors such as 2B4, CD160, Tim-3 
and KLRG1 occurred in about half of HCV-specific CD8+ T cell responses and correlate with 
low or intermediate level of CD127 expression, impaired proliferative capacity, an 
intermediate T cell differentiation stage (Bengsch et al., 2010). These data indicates that HCV 
infection modulates different negative co-stimulatory molecules to favor the development of 
HCV-specific CD8+ T cell exhaustion. On the other hand, HCV infection is also able to 
regulate pro-apototic pathways to induce HCV-specific T cell deletion in order to escape 
from immune response. HCV-specific CTLs from chronic patients targeting the virus 
express an exhausted phenotype associated to the up-regulation of the pro-apototic 
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molecule Bim. The activity of this molecule is contra-regulated by the anti-apoptotic 
molecule Mcl-1. Interestingly, the reactivity of these cells is impaired but can be restored by 
blocking apoptotic pathways (Larrubia et al., 2011).  
In summary, HCV is able to impair adaptive immune response at different levels. The 
effector population in charged of HCV clearing is defective because HCV is able to induce 
on those cells anergy and apoptosis (Fig.-5). Moreover, HCV is able to escape humoral 
response and cellular response by escape mutations in immunodominant epitopes. Finally, 
HCV is also quite efficient in the impairment of the specific T helper response, which is 
essential to organize the humoral and cellular response. To perform all these immune-
escape strategies, HCV takes advantage of the pro-anergenic environment of the infected 
liver, because HCV-specific T cell priming at this level is not efficient to develop adequate 
effector cells. As it was commented for HBV infection, HCV immune response restoration 
could be an interesting therapeutic tool to help in viral clearance in chronic patients.  
4. Accepted model of HBV&HCV pathogenesis  
As previously commented, specific CTLs play a central role in HBV&HCV 
immunopathogenesis. These cells are able to kill some infected hepatocytes inducing a 
minor liver damage, but also they secrete type-I cytokines responsible for non-cytopathic 
virus clearing. To attract these cells into the liver the infected hepatocytes secrete another 
kind of cytokines called chemokines. The migration of lymphocytes to the liver is a complex 
process including adhesion, rolling, triggering, and transendothelial migration. Chemokines 
and their receptors play an essential role in this multistep pathway (Springer, 1994). During 
primoinfection, when the adaptive immune system is not able to control infection, the 
infected hepatocytes continue secreting chemokines to try to attract more defensive cells. In 
viral chronic hepatitis, the expression of different chemokines in the liver has been 
described. CXCL-10 is increased in the liver and peripheral blood during viral chronic 
hepatitis (Larrubia et al., 2007; Shields et al., 1999; Tan et al., 2010; Wang et al., 2008). This 
molecule is produced by hepatocytes and sinusoidal endothelial cells. Moreover, CXCL9 
and CXCL11 are also increased in serum and liver of subjects with chronic viral hepatitis 
(Bieche et al., 2005). CXCL9 is detected primarily on sinusoidal endothelial cells, while 
CXCL-11 is produced mainly by hepatocytes (Apolinario et al., 2002). CCL5 intrahepatic 
expression is also elevated in viral chronic hepatitis and is produced by hepatocytes, 
sinusoidal endothelial cells and biliary epithelium. Finally, several studies have reported an 
increased level of CCL3 and CCL4 either in the liver or in serum. These molecules are 
detected on endothelial cells, on some hepatocytes and biliary epithelial cells (Apolinario et 
al., 2004). The expression of all these chemokines in the liver can be induced directly by viral 
proteins. Previous reports have shown a high hepatocyte synthesis of CXCL10, CXCL9 and 
CCL5, induced by some HCV proteins such as NS5A and core (Apolinario et al., 2005), 
although a recent in-vitro study suggests that HCV proteins could also decrease CCL5 and 
CXCL10 genes expression (Sillanpaa et al., 2008). All these chemokines recruit T cells with a 
Th1/Tc1 phenotype, expressing specific chemokine receptors such as CCR5 and CXCR3. 
The non-ELR-CXC chemokine attracts CXCR3 expressing T cells while CC chemokine 
attract CCR5 expressing T cells to the liver. Consequently, in viral chronic hepatitis, an 
intrahepatic enrichment of CCR5 and CXCR3 expressing T cells, located in hepatic lobule 
and portal tracts has been shown, while these populations are very infrequent in uninfected 
subjects (Bertoletti & Maini, 2000; Larrubia et al., 2008) (Fig.- 6). 
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Persistent HBV&HCV infection is characterized by a non-specific inflammatory infiltrate in 
the liver, mainly of CD8+ cells (Sprengers et al., 2005), responsible for liver damage. These 
cells are attracted by the interaction between the intrahepatic secreted chemokines and the 
chemokine receptors expressed on T cells. Actually, previous reports have shown a 
correlation between liver inflammation and liver infiltrating CXCR3/CCR5 expressing T 
cells. The frequency of these cells was positively correlated with portal and lobular 
inflammation but not with liver fibrosis (Larrubia et al., 2007). These data suggest that CCR5 
and CXCR3 could play an important role in chronic liver damage by means of inflammatory 
T cells recruitment into the liver. Moreover, several previous studies have also shown a 
correlation between liver inflammation and chemokine levels. Intrahepatic CXCL10 mRNA 
levels are associated with intralobular inflammation (Harvey et al., 2003). Similarly, CXCL9 
and CXCL11 correlate with the grade of liver inflammation (Helbig et al., 2004). 
Furthermore, CC chemokines are also correlated with the intrahepatic inflammatory activity 
(Kusano et al., 2000). Clearly, intrahepatic CCL5 positive cells correlate with the 
inflammatory activity. Bearing in mind all the previous data it is possible to speculate that 
 
 
Fig. 6. Scheme showing the role of T cell intrahepatic recruitment according to the degree of 
liver damage and viral control. In resolved HBV/HCV infection an adequate effector T cell 
response is attracted to the liver to clear the virus. After that, a memory T cell population is 
continuously patrolling the liver to keep under control viral traces. Nevertheless, in 
persistent infection after specific T cells failure to control infection, a non-specific 
immflamatory infiltrate is sequestered into the liver, responsible of the persistent liver 
damage. 
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chemokines are secreted in the infected liver to attract an adaptive immune response able to 
clear the virus. Unfortunately, when the specific response fails these chemokines also attract 
non-specific mononuclear and polymorphonuclear cells, which are not able to remove the 
virus but produce liver inflammation (Kakimi et al., 2001). Therefore, as chemokines are 
nonspecific chemoattractants, intrahepatic inflammatory infiltrate during chronic infection 
is mainly non-virus-specific and consequently unable to eliminate the infection, but able to 
produce cytokines capable of initiating and perpetuating hepatic fibrogenesis (Bertoletti & 
Maini, 2000; Bertoletti et al., 2010; Friedman, 2003; Larrubia et al., 2008). 
5. Mechanisms to restore adaptive immune response in HBV&HCV infection  
Bearing in mind that specific T responses are essential to control HCV during natural 
immune response, several studies have been performed to analyze the role of different 
therapeutic approaches on T cell response to know whether it is possible to reverse T cell 
dysfunction in-vivo. Longitudinal analysis of HBV-specific responses during IFN- 
treatment did not show a significant increase of these responses during treatment 
(Sprengers et al., 2007). Nevertheless, it was observed an improvement after treatment in 
patients with resolved infection (Carotenuto et al., 2009). During HCV infection, the same 
scenario was observed (Barnes et al., 2002), although some studies have demonstrated a 
restoration of T cell response in sustained viral responders (Kamal et al., 2002). However, 
patients presenting a better HCV-specific CD8 cell proliferative potential at baseline, are 
more likely to present a rapid and sustained viral response. Moreover, after treatment a 
HCV-specific T-cell response enhancement is observed in sustained viral responders (Pilli et 
al., 2007). The absence of T cell reactivity improvement during treatment could be due to the 
direct anti-proliferative effect of IFN-. Obviously, this effect could counteract the positive 
consequence of decreasing viral pressure on specific-T cells during treatment. Nevertheless, 
these data also could suggest that is important to restore a specific T cell response, at least at 
the end of treatment, to keep under control residual viral traces. In HBV infection, several 
papers dealing with the role of nucleot(s)ide analogues (NUCs) treatment on anti-HBV 
immune response have shown that they are able to reconstitute temporally HBV-specific 
CD4 and CD8 responses (Boni et al., 1998; Cooksley et al., 2008). Moreover, these treatments 
can decrease the frequency of Tregs during treatment (Stoop et al., 2007) and specifically to 
decrease the ratio Treg:Th17 (Zhang et al., 2010). These data suggest that the NUCs are 
controlling the infection not only through an anti-viral effect but also helping to restore 
specific immune response. In any case, all these effects on specific T cells are partial and 
limited in time. For that reason other immunoregulatory therapeutic approaches are being 
considered. Several pre-clinical studies have been performed to try to restore HBV/HCV 
specific responses in-vitro and in animal models. Modulation of negative co-stimulatory 
molecules, in addition to blocking immunosupressive cytokines could be promising 
strategies to restore an effective T cell response. The modulation of negative co-stimulatory 
molecules, such as PD-1, CTLA-4, Tim-3, has shown in-vitro to increase specific-T cell 
reactivity. This can be also enhanced using Abs to block the regulatory cytokine IL-10. 
Experts in immunotherapy have suggested that after restoring a T cell response could be 
necessary to boost that response using a therapeutic vaccine. Although these results seem to 
be quite promising, the blockade of negative co-stimulatory pathways in addition to IL-10 
could lead to the development of autoimmune diseases, which could prevent the use of this 
strategy as a therapeutic tool in humans. Therefore, more research is necessary in this field 
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before these strategies are suitable for the treatment of chronic viral infections (Ferrari, 2008; 
Fisicaro et al., 2010; Larrubia et al., 2011; Nakamoto et al., 2009). 
6. Conclusions  
HBV & HCV are two hepatotropic non-cytopathic viruses able to develop a chronic liver 
disease. The innate immune response is defective in both infections, residing the viral 
control in the efficacy of adaptive immune response. HBV&HCV specific CTL response play 
a central role in viral control through cytopathic and non-cytopathic mechanisms. 
Nevertheless, during persistent infection, adaptive response is impaired due to exhaustion 
and deletion. Several in-vitro strategies have shown to be effective in its restoration but it is 
necessary more research before these approaches can be applied to clinical practice. Finally, 
when the virus is not controlled by adaptive response a non-specific inflammatory infiltrate 
is attracted to the liver which is responsible for the persistent low-grade liver damage, 
allowing the generation of liver fibrosis during disease progression. 
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